Cardiovascular
Rheumatic heart disease
An autoinflammatory condition following an infection with Group A Beta Hemolytic Streptococcus (GABHS), in which the heart is attacked by antibodies formed in reaction to a recent GABHS infection. Chief anatomic changes of the valve include leaflet thickening, commissural fusion, and shortening and thickening of the tendinous cords, all of which can result in valvular dysfunction.
Starter kit · coming soon
Start building on rheumatic heart disease
Open datasets
Imaging, genomics, clinical and text data you can use today
Benchmarks
Existing tasks and leaderboards to measure against
Open questions
Unsolved problems where a model could help
See a finished example: the malaria starter kit →
Where the field stands
01
Early understanding
No strong gene target or drug candidate yet
02
Target found
At least one gene target with strong evidence
03
Drug candidates
Preclinical or phase 1 drug candidates
04
In trials
Drug candidates in phase 2 or later
05
Has approved drugs
At least one approved drug; not necessarily a cure
Derived from Open Targets drug and target data, not self-reported.
Healthy years lost (DALYs), 2023
14.5M
95% range 10.1M to 19.9M
Deaths, 2023
389k
People living with it, 2023
54.9M
GBD cause: Rheumatic heart disease (exact match)
Research attention
What there is to build on
Open Targets Platform ↗Gene targets with strong evidence
2
of 501 associated genes
Top associated genes
FBN1TTNTGFB2LPAZFHX3
Drugs and clinical candidates
8
Approved drugs
0
Identifiers
- Open Targets
- MONDO_0006955
- MeSH
- D012214
Trial and paper counts are rough measures of attention, not of progress. This page is for research planning, not medical advice.